DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20150408

Study of intravenous ferric carboxy maltose in iron deficiency anemia in women attending gynecological clinic - safety and efficacy

Vineet V. Mishra, Nisarg Dharaiya, Rohina Aggarwal, Sumesh Choudhary, Khushali Gandhi

Abstract


Background: Several intravenous iron preparations are available for the treatment of iron deficiency anemia (IDA). Some of these require multiple small infusions to prevent labile iron reactions while iron dextran (DEX) is associated with a risk of potentially serious anaphylactic reactions. Ferric carboxymaltose (FCM), a nondextran intravenous iron, is an effective and a safe option which can be administered in high single doses without serious adverse effects.

Methods: It was a prospective study including 150 women of age >18 years with a definitive diagnosis of IDA and Hemoglobin (Hb) between 7-10 gm% from December 2013 to October 2014.Out of these, eleven women were lost to follow up and were excluded from the study. Intravenous FCM (500-1000mg) was administered and the improvement in Hb levels and iron stores was assessed after 3 weeks of total dose infusion.

Results: Out of 150, 139 women were included in the study. Most of the women were in the age group of 30-39 years (38.12%). Most of the patients (74.10%) had mild anemia. Mean Hb levels increased over a period of 3 weeks after FCM administration from 8.70±1.04 gm% to 11.07±1.02 gm% which was statistically significant. Other parameters like S.TIBC (Serum total iron binding capacity), S. Ferritin, S. Iron also suggested a significant improvement after FCM administration. No serious life threatening adverse events were observed with FCM.

Conclusion: Intravenous FCM is an effective and a safe treatment option for IDA and has an advantage of single administration of high doses without serious adverse effects.


Keywords


Anaemia in Indian women, Iron therapy, Injectable iron preparations and it's efficacy

Full Text:

PDF

References


Killip S, Bennett J, Chambers M. Iron deficiency anemia. Am Fam Physician. 2007;75:671–8.

Silverstein SB, Gilreath JA, Rodgers GM. Intravenous iron therapy: a summary of treatment options and review of guidelines. Journal of Pharmacy Practice, 2008; 21(6):431–43.

Lyseng-Williamson KA, Keating GM. Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. Drugs. 2009;69(6):739-56.

Qunibi W. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review. Arzneimittelforschung. 2010;60:399–412.

Van Wyck DB, Martens MG, Seid MH, Baker JB, Mangione A. Intravenous ferric carboxymaltose compared with oral iron in the treatment of postpartum anemia: a randomized controlled trial. Obstetrics and Gynecology. 2007;110(2):267–78.

Goodnough LT, Van Wyck DB, Mangione A, Morrison J, Hadley PE, Jehle JA. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial. Transfusion. 2009;49(12):2719–28.

Bregman DB, Goonough LT. Experience with intravenous ferric carboxymaltose in patients with iron deficiency anemia Ther Adv Hematol. 2014;5(2):48–60.

Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B, et al. FERGI Study Group FERGIcor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterology. 2011;141(3):846-53.

Hussain I, Bhoyroo J, Butcher A, Todd A. Koch, Andy He and David B. Bregman. Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency Anemia. Anemia. Volume 2013 (2013), Article ID 169107, 10 pages.

Barish CF, Koch T, Butcher A, Morris D, Bregman DB. Safety and efficacy of intravenous ferric carboxymaltose (750 mg) in the treatment of iron deficiency Anemia: two randomized, controlled trials. Anemia 2012;2012:1-12.

Charytan C, Bernardo MV, Koch T, Butcher A, Morris D, Bregman DB. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study. Nephrology Dialysis Transplantation. 2013;28:953–64.

Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. Journal of Bone and Mineral Research. 2013;28(8):1793–803.

Anker SD, Colet JC, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. The New England Journal of Medicine. 2009;361(25):2436–48.

Kulnigg S, Stoinov S, Simanenkov V, et al. A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. American Journal of Gastroenterology. 2008;103(5):1182–92.